Showing 1,341 - 1,360 results of 3,189 for search '"vaccination"', query time: 0.13s Refine Results
  1. 1341

    How have Ontario Public Health units engaged with faith-based organizations to build confidence in COVID-19 vaccines among ethno-racial communities. by Kadidiatou Kadio, Melodie Yunju Song, Anna Karbasi, Denessia Blake-Hepburn, Shaza A Fadel, Sara Allin, Anushka Ataullahjan, Erica Di Ruggiero

    Published 2024-01-01
    “…The second phase involved a three-stage engagement process:1) Consultation and information sharing was employed to facilitate early and open dialogue. 2) Work with FBOs and interested communities to plan vaccine deployment strategies to meet the needs of different faith and ethno-racial groups, and jointly plan the implementation of vaccination clinics. 3) Share roles and responsibilities with FBOs to roll out vaccine confidence strategies. …”
    Get full text
    Article
  2. 1342
  3. 1343
  4. 1344
  5. 1345

    LEAPS Vaccine Incorporating HER-2/neu Epitope Elicits Protection That Prevents and Limits Tumor Growth and Spread of Breast Cancer in a Mouse Model by Ken S. Rosenthal, Sarah Stone, Gary Koski, Daniel H. Zimmerman

    Published 2017-01-01
    “…When administered as a prophylactic vaccination before tumor challenge, J-HER protected against tumor development for at least 48 days. …”
    Get full text
    Article
  6. 1346
  7. 1347
  8. 1348

    Pre-existing IgG antibodies to HCoVs NL63 and OC43 Spike increased during the pandemic and after COVID-19 vaccination by Zahra Hasan, Kiran Iqbal Masood, Marc Veldhoen, Shama Qaiser, Marta Alenquer, Mishgan Akhtar, Sadaf Balouch, Junaid Iqbal, Yaqub Wassan, Shahneel Hussain, Khalid Feroz, Sajid Muhammad, Atif Habib, Akbar Kanji, Erum Khan, Afsar Ali Mian, Rabia Hussain, Maria Joao Amorim, Zulfiqar A. Bhutta

    Published 2025-02-01
    “…Vaccinees were sampled prior to vaccination as well after 6, 12 and 24 weeks after COVID-19 inactivated (Sinovac), or mRNA (BNT162b2) vaccine administration.PPC sera showed seropositivity of 15 % to SARS-CoV-2, whilst it was 45 % in the HC 2021 group. …”
    Get full text
    Article
  9. 1349
  10. 1350

    Specific Immune Responses and Oncolytic Effects Induced by EBV LMP2A-Armed Modified Ankara-Vaccinia Virus Vectored Vaccines in Nasopharyngeal Cancer by Liying Sun, Chao Liu, Junping Peng

    Published 2025-01-01
    “…Methods: The modified vaccinia virus Ankara (MVA) is universally used in vector vaccine research because of its excellent safety profile and highly efficient recombinant gene expression. …”
    Get full text
    Article
  11. 1351
  12. 1352

    Unilateral Anterior Scleritis Following the Booster Shot of Inactivated COVID-19 (Sinopharm) Vaccine in a 52-Year-Old Woman: A Case Report by Kimia Jazi, Mahnaz Rahimi, Fatemeh Hasani, Maryam Shirmohammadi, Maryam Masoumi

    Published 2024-01-01
    “…Since the birth of vaccines, adverse reactions accompanied the immunity, and COVID-19 vaccines are no exceptions. …”
    Get full text
    Article
  13. 1353
  14. 1354
  15. 1355
  16. 1356
  17. 1357
  18. 1358
  19. 1359
  20. 1360